C4X Discovery receives latest milestone payment from Sanofi

Core Insights - C4X Discovery Holdings Ltd has received an €8 million milestone payment from Sanofi due to progress in its oral IL-17A inhibitor program [1][2] - The total potential milestone payments from the license agreement with Sanofi could reach €414 million, including royalties on future net sales [2] - The oral IL-17A inhibitor aims to treat inflammatory diseases, representing a significant market opportunity [3] Company Developments - C4X Discovery has now received a total of €18 million in upfront and pre-clinical payments from Sanofi [2] - The CEO of C4X Discovery highlighted the importance of this milestone as a recognition of the company's drug discovery capabilities [4] - The Chairman noted the progress of the oral IL-17A inhibitor program reflects the growing value of C4X's broader pipeline, which includes multiple partnered and high-value programs [4] Industry Context - The IL-17A inhibitor program targets a multi-billion-dollar market for inflammatory disease treatments, providing an oral alternative to current injectable biologic therapies [3] - C4X Discovery's approach combines scientific expertise with advanced technologies to develop small molecule drug candidates for immuno-inflammation [6]